Episealer® presented at Italian knee congress
Episurf Medical (Nasdaq: EPIS B) today announces that the company’s founder and board member, Prof. Leif Ryd, has been invited by S.I.G.A.S.C.O.T (Società Italiana del Ginocchio Artroscopia Sport Cartilagine Tecnologie Ortopediche) to present Episealer® and how the individualised knee implant fits into the treatment algorithm for patients presenting with cartilage lesions. The congress, Bone Edema Today, is arranged in Naples, Italy on October 12, and is a meeting for leading Italian and international knee surgeons.
“We are very happy about the fact that Prof. Ryd has been invited to this meeting to present Episealer®. As the Italian agenda item suggests, “Episurf - le nuove frontiere del mini metallo”, our technology is something new, and it generates more and more interest as it contributes to a solution for an orthopaedic problem of significant size globally” says Pål Ryfors, CEO Episurf Medical.
On September 4, 2019, Episurf Medical announced that the knee implant Episealer® has been registered and approved for sale in Italy.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
Tags:
